Targeting the mechanisms of drug resistance in mantle cell lymphoma
Mechanism-Based Targeting of Mantle Cell Lymphoma
This study is looking at why mantle cell lymphoma sometimes stops responding to treatment, and it's for patients who want to help researchers find better ways to fight this cancer by testing a new drug alongside current therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10478980 on NIH RePORTER |
What this research studies
This research focuses on understanding why mantle cell lymphoma (MCL) becomes resistant to treatments, which is a significant challenge in managing this type of cancer. By investigating the genomic and molecular mechanisms behind drug resistance, the researchers aim to develop more effective therapies that can be tailored to individual patients. The approach includes using a drug called palbociclib to halt cancer cell proliferation and enhance the effectiveness of existing treatments like ibrutinib. Patients will be monitored through biopsies to assess their response to these therapies over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who have experienced treatment resistance.
Not a fit: Patients with other types of lymphoma or those who have not been diagnosed with mantle cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and durable treatment options for patients with mantle cell lymphoma.
How similar studies have performed: Previous research has shown promise in targeting drug resistance in other cancers, suggesting that this approach may also be effective for mantle cell lymphoma.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Chen-Kiang, Selina Y — Weill Medical Coll of Cornell Univ
- Study coordinator: Chen-Kiang, Selina Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.